Sandoz Gets Canada Approval for Generic Version of Ozempic

Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth

Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

Sandoz Shares Climb After Biosimilar Sales Drive Growth

Sandoz results narrowly beat sales expectations

Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations

Sandoz agrees $450 mln settlement with 43 US states over antitrust claims

Generic drug sector seeks policy fixes after Trump tariff threat

Generic drugmaker Sandoz to engage with US after Trump tariff threat

FDA set to review Sandoz's generic GLP-1s

Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports

Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown

Sandoz Shares Jump on Improved Guidance

Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz

Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2